Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies.
Sarah P. Blagden(Churchill Hospital), Christopher McGuigan(University College Dublin), Ajithkumar Sukumaran(Imperial College London), Andrea Rockall, Hani Gabra(Royal Children's Hospital), Essam Ghazaly(Queen Mary University of London), Markand Patel(Hammersmith Hospital), Naomi Loyse(NIHR Wellcome Trust Southampton Clinical Research Facility), Nagy Habib(Hammersmith Hospital), Puvan Suppiah(Hammersmith Hospital), Harpreet Wasan(Peter MacCallum Cancer Centre), John G. Gribben(Queen Mary University of London), Mona El‐Bahrawy(Al-Azhar University), Nishat Bharwani(Imperial College Healthcare NHS Trust), Daniel O’Shea(Wellcome Trust), Chara Stavraka(King's College London), Robert Leonard(National Cancer Centre Japan), Ivana Rizzuto(Imperial College Healthcare NHS Trust)
Cited by 7
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k